

# Oral Abstract sessions

CODE	TITLE	DAY	START	END	TRACK 1	TRACK 2
OA-01	TB preventive therapy in HIV	21 OCT	11:00	12:20	B8	D8
OA-02	Finding a needle in the haystack: where are children with TB?	21 OCT	11:00	12:20	B6	B7
OA-03	Optimising lung health beyond TB	21 OCT	11:00	12:20	Track B	Track D
OA-04	A holistic approach: experiences from Europe	21 OCT	11:00	12:20	C8	C9
OA-05	Innovative TB diagnostics	21 OCT	12:30	13:50	B1	A3
OA-06	Different approaches to improve treatment and care	21 OCT	15:00	16:20	C8	C9
OA-07	Moving away from isoniazid for TB preventive treatment	21 OCT	15:00	16:20	C1	B7
OA-08	The Union student late-breaker session on lung health	21 OCT	15:00	16:20		
OA-09	What person-centred care really means	21 OCT	16:30	17:50	C8	C9
OA-10	Partnerships for integrating services	22 OCT	11:00	12:20	C9	C2
OA-11	New solutions to old TB challenges	22 OCT	11:00	12:20	B1	Track A
OA-12	Confronting TB stigma	22 OCT	12:30	13:50	E2	E3
OA-13	The race for improved multidrug-resistant care	22 OCT	12:30	13:50	C3	C9
OA-14	COVID-19: the great disrupter	22 OCT	12:30	13:50	D13	C15
OA-15	TB preventive therapy: we need to do better	22 OCT	12:30	13:50	C1	B7
OA-16	TB Xpert in low- and middle-income countries: ensuring quality and quantity	22 OCT	12:30	13:50	C11	B1
OA-17	Safety first: side effects of old and new drugs	22 OCT	12:30	13:50	B2	C3
OA-18	(Im)possible mission: TB care in low-resourced settings	22 OCT	15:00	16:20	C2	B1

<b>CODE</b>	<b>TITLE</b>	<b>DAY</b>	<b>START</b>	<b>END</b>	<b>TRACK 1</b>	<b>TRACK 2</b>
OA-19	Histories of success: improving TB and latent TB infection care	22 OCT	15:00	16:20	C9	Track B
OA-20	The Union late-breaker session on COVID-19	22 OCT	15:00	16:20		
OA-21	Finding missing people with TB: targeted approaches	22 OCT	16:30	17:50	E1	C9
OA-22	Improving the quality of care	23 OCT	11:00	12:20	C9	D1
OA-23	TB: finding the missing millions	23 OCT	11:00	12:20	B6	C2
OA-24	TB and diabetes	23 OCT	11:00	12:20	B8	B9
OA-25	TB: deep into molecular structure	23 OCT	11:00	12:20	D5	B1
OA-26	Using digital technology for TB elimination	23 OCT	12:30	13:50	C9	C8
OA-27	The social impact of TB in Europe	23 OCT	12:30	13:50	Europe track	
OA-28	New and old tests for latent TB infection	23 OCT	15:00	16:20	C1	B7
OA-29	Who pays the cheque? The economic burden of TB	23 OCT	15:00	16:20	D10	C9
OA-30	The HIV-TB and diabetes late-breaker session	23 OCT	15:00	16:20		
OA-31	TB epidemiology	23 OCT	16:30	17:50	D1	D2
OA-32	Reaching the most vulnerable	24 OCT	11:00	12:20	D5	D1
OA-33	Overcoming impediments in tobacco control	24 OCT	11:00	12:20	C14	B10
OA-34	Risk factors, surveillance and control strategies in potential zoonotic TB hotspots	24 OCT	11:00	12:20	F4	Track D
OA-35	New and existing TB drug resistance	24 OCT	11:00	12:20	A3	B1
OA-36	The role of pharmacies in the TB cascade of care	24 OCT	12:30	13:50	C9	Track B
OA-37	TB and HIV potpourri	24 OCT	12:30	13:50	B8	D8
OA-38	Diagnostic assays quality and accuracy	24 OCT	12:30	13:50	B1	A3
OA-39	The Union/CDC late-breaker session on TB	24 OCT	15:00	16:20		
OA-40	Health and well-being post-TB	24 OCT	15:00	16:20	D7	C7
OA-41	TB detection and treatment in mothers and children	24 OCT	15:00	16:20	C4	C6

*All session times are shown in Central European Summer time*

# Symposia

CODE	TITLE	DAY	START	END	TRACK 1	TRACK 2
SP-01	Strengthening evidence on optimal treatments for multidrug-resistant TB: approaches to studying timing and duration.	21 OCT	11:00	12:20	B2	
SP-02	Tests for the detection of TB infection - tuberculin skin test vs interferon-gamma release assays.	21 OCT	11:00	12:20	C1	
SP-03	When novel product bans are best: lessons learned and challenges faced in tackling tobacco in low-and middle-income countries.	21 OCT	12:45	13:45	C14	C13
SP-04	Advancing TB prevention in children during the COVID-19 pandemic	21 OCT	12:30	13:50	C4	C6
SP-05	Updating World Health Organization TB screening guidelines: evidence reviews of the yield, tools and costs of screening.	21 OCT	12:30	13:50	B6	C9
SP-06	The people-centred framework for national and subnational TB planning and programming - early adopters share lessons learned and experiences	21 OCT	12:30	13:50	C10	
SP-07	Towards new TB vaccines: progress and considerations for introduction	21 OCT	12:30	13:50	A2	C1
SP-08	Incarceration for drug use and TB among people who use drugs – time to break the cycle.	21 OCT	15:00	16:20	E1	E2
SP-09	Ending TB in vulnerable populations through operational research, capacity building and evidence-informed decision making in Eastern Europe and Central Asia (Find-Treat-All).	21 OCT	15:00	16:20	B6	B8
SP-10	High-dose rifapentine with or without moxifloxacin for shortening treatment of TB: TB Trials Consortium Study 31/ACTG A5349 phase III clinical trial results	21 OCT	16:30	17:50	B2	
SP-11	Treating mild asthma: a paradigm shift	21 OCT	16:30	17:50	B9	C10

CODE	TITLE	DAY	START	END	TRACK 1	TRACK 2
SP-12	Scale-up of joint action on diabetes and TB – lessons from the field	21 OCT	16:30	17:50	B8	C8
SP-13	Deadly partners - COVID-19, non-communicable diseases and tobacco	21 OCT	16:30	17:50	C10	C15
SP-14	Is TB elimination in the European Region a realistic goal?	21 OCT	16:30	17:50	C10	D1
SP-15	Short, all-oral regimens for rifampicin-resistant TB: progress towards programmatic implementation at country level.	22 OCT	11:00	12:20	C3	C10
SP-16	Health system response preventing TB and tobacco - lessons learned from COVID-19	22 OCT	11:00	12:20	C14	
SP-17	Detecting TB among people living with HIV: updated options with updated guidance	22 OCT	11:00	12:20	C11	
SP-18	The work of the WHO European Laboratory Initiative on TB, HIV and viral hepatitis	22 OCT	11:00	12:20	C11	B1
SP-19	Household and close contact investigation: a key gateway to TB prevention and case detection in children.	22 OCT	12:30	13:50	C4	
SP-20	Improving access to laboratory-based diagnosis for young children - recent advances using stool and urine as alternative sample types.	22 OCT	15:00	16:20	C4	
SP-21	Engaging communities to address concurrent pandemics of TB and COVID-19	22 OCT	15:00	16:20	E1	C15
SP-22	Advancing a prevention research agenda for TB	22 OCT	16:30	17:50	A2	A3
SP-23	Preventing TB in people with diabetes mellitus: where are we now and where are we going?	22 OCT	16:30	17:50	B8	B7
SP-24	The impact of COVID-19 on TB research and development and access: it's a two-way street	22 OCT	16:30	17:50	C10	
SP-25	It takes more than bandwidth - using the Extension for Community Healthcare Outcomes virtual community of practice model to build local health workforce capacity.	22 OCT	16:30	17:50	C12	C9
SP-26	Leveraging a multiplex platform for TB, HIV and coronavirus for diagnostic testing and clinical monitoring: country experiences	22 OCT	16:30	17:50	C11	C15
SP-27	Exploring existing and potential uses of artificial intelligence for TB programming	23 OCT	11:00	12:20	D9	
SP-28	My care, my metrics: why patient definitions of person-centred care are critical	23 OCT	11:00	12:20	C8	
SP-29	TB in pregnancy: what's new in prevention and treatment?	23 OCT	11:00	12:20	C6	
SP-30	Towards a TB-free childhood: best practices to find, cure and prevent TB in children in Africa.	23 OCT	12:30	13:50	C4	

*All session times are shown in Central European Summer time*

CODE	TITLE	DAY	START	END	TRACK 1	TRACK 2
SP-31	Challenges and issues in ensuring continuum of care for migrants crossing borders with TB.	23 OCT	12:30	13:50	E2	
SP-32	Regional studies that are improving the zoonotic TB scientific evidence base.	23 OCT	12:30	13:50	F3	F4
SP-33	Role and contribution of algorithm and score for diagnosis of paediatric TB.	23 OCT	12:30	13:50	B1	
SP-34	Human rights and tobacco – progress and next steps for protecting populations from tobacco industry interference in child health.	23 OCT	15:00	16:20	E3	E1
SP-35	Migration journeys and the risk for TB – what do we know and what do we need to find out?	23 OCT	15:00	16:20	E2	
SP-NAP	TB educational material discussion session	23 OCT	15:00	16:20	C12	
SP-36	Human-centred design to advance patient-centred TB care in low-income countries	23 OCT	16:30	17:50	C8	
SP-37	Strategies for addressing barriers for LGBTQIA in accessing high quality TB care – a comparative analysis with HIV.	23 OCT	16:45	17:45	E2	
SP-38	Hidden, but for how much longer? The epidemiological and economic burden of post-TB.	23 OCT	16:30	17:50	D7	D9
SP-39	National TB prevalence surveys in Southern Africa: key results, lessons learned and programmatic implications	23 OCT	16:30	17:50	D1	B6
SP-40	Implementation and scale-up of TB preventive treatment: overcoming challenges to reach people living with HIV	23 OCT	16:30	17:50	C1	
SP-41	Preventing human rights abuses in the digitisation of the TB and COVID-19 responses.	24 OCT	11:00	12:20	E3	C15
SP-42	Take home messages for active case finding learned from TB prevalence surveys, TB or not TB?	24 OCT	11:00	12:20	D1	
SP-43	COVID-19 in pregnant women	24 OCT	12:30	13:50	C6	C15
SP-44	Self-clearance of <i>Mycobacterium tuberculosis</i> infection: needs and consequences	24 OCT	12:30	13:50	D5	B7
SP-45	Modelling to advance prevention	24 OCT	12:30	13:50	D9	
SP-46	Subclinical TB disease: lessons and questions from field to lab	24 OCT	15:00	16:20	D5	D1
SP-47	Youth mobilisation to boost the fight to End TB	24 OCT	15:00	16:20	C9	E2
SP-48	Understanding the impact of participatory approaches in developing sustainable TB policies	24 OCT	15:00	16:20	E1	C10

# E-poster sessions

All E-posters are live for 24 hours

CODE	TITLE	DAY	START	TRACK 1	TRACK 2
EP01	Resisting the resistance	21 OCT	10:00	C3	B2
EP02	Challenges for randomised controlled trials on TB treatment	21 OCT	10:00	B4	B2
EP03	Digital technology in the fight against TB	21 OCT	10:00	C9	B6
EP04	Learning from epidemiological analyses	21 OCT	10:00	Track D	D1
EP05	Person-centred care: the advantages and challenges	21 OCT	10:00	C8	C9
EP06	TB: data matters	21 OCT	10:00	C9	Track B
EP07	Improving TB care in children	21 OCT	10:00	Track B	C1
EP08	COVID-19 and TB: friends or foes?	21 OCT	10:00	C15	D13
EP09	Improved acceptability of TB regimens needed	21 OCT	10:00	C3	B2
EP10	Overcoming barriers in the contact cascade of care	21 OCT	10:00	C1	B6
EP11	TB: HIV and diabetes comorbidities	22 OCT	10:00	B8	D8
EP12	Approaches to paediatric TB prevention, diagnosis and treatment	22 OCT	10:00	C4	Track B
EP13	Improving all steps of the TB cascade of care: from identification to beyond treatment	22 OCT	10:00	B6	C2
EP14	Reaching the hard-to-reach ones: strategies to overcome the challenges	22 OCT	10:00	C9	B6
EP15	All hands on deck: key stakeholders take initiative to end TB	22 OCT	10:00	E1	E2
EP16	TB: new insights on cost and cost-effectiveness	22 OCT	10:00	D10	C9
EP17	Facing TB during the COVID-19 pandemic	22 OCT	10:00	C9	C3
EP18	Scaling up TB preventive therapy: it is about time!	22 OCT	10:00	C1	Track B

All session times are shown in Central European Summer time

CODE	TITLE	DAY	START	TRACK 1	TRACK 2
EP19	Quality and modelling of TB	22 OCT	10:00	B6	B1
EP20	Community healthcare workers in evidence	23 OCT	10:00	B6	C9
EP21	TB as an occupational hazard	23 OCT	10:00	D6	C1
EP22	TB adherence to treatment	23 OCT	10:00	C3	C8
EP23	TB in children and adolescents	23 OCT	10:00	D2	C4
EP24	TB innovative strategies to find the missing cases	23 OCT	10:00	C9	B6
EP25	Lung health across the lifespan	23 OCT	10:00	Track B	Track D
EP26	Improving knowledge: the benefits for person-centred TB care	23 OCT	10:00	C12	C8
EP27	Difficult problems in TB infection and treatment	23 OCT	10:00	Track A	B1
EP28	Making the most of short money to fight TB	23 OCT	10:00	D10	D9
EP29	The European TB experience	24 OCT	10:00	Track C	Europe track
EP30	Where are the undiagnosed TB cases?	24 OCT	10:00	B6	C9
EP31	Allied against TB: new and old partners	24 OCT	10:00	C9	C2
EP32	Quality improvement of the TB cascade of care	24 OCT	10:00	Track A	B6
EP33	Barriers in the TB care cascade: it's time for local solutions	24 OCT	10:00	E2	E1
EP34	TB: from bench to the bedside	24 OCT	10:00	Track B	Track C
EP35	Ongoing battle against the tobacco industry	24 OCT	10:00	C13	C14
EP36	Molecular testing for TB infection and drug resistance	24 OCT	10:00	A3	B1
EP37	Joining efforts for TB elimination: the role of the private sector	24 OCT	10:00	C9	B6

# TBScience sessions

CODE	TITLE	DAY	START	END	TRACK 1
TBS1A	Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies – Plenary session	21 OCT	15:00	16:30	TBScience
TBS1B	Role of innate and adaptive immunity in TB, and evaluation of immune correlates in preclinical and clinical studies – Oral abstract presentations	21 OCT	16:30	17:15	TBScience
TBS1C	Role of innate and adaptive immunity in TB, and evaluation of immune correlates in preclinical and clinical studies – Panel discussion	21 OCT	17:15	18:00	TBScience
TBS2A	Dead or alive? Implications of spectrum of <i>M. tuberculosis</i> infection – Plenary session	22 OCT	15:00	16:30	TBScience
TBS2B	Dead or alive? Implications of spectrum of <i>M. tuberculosis</i> infection – Oral abstract presentations	22 OCT	16:30	17:15	TBScience
TBS2C	Dead or alive? Implications of spectrum of <i>M. tuberculosis</i> infection – Round table	22 OCT	17:15	18:00	TBScience
TBS3A	Resistance to new drugs – Plenary Session	23 OCT	15:00	16:30	TBScience
TBS3B	Resistance to new drugs – Oral abstract presentations	23 OCT	16:30	17:15	TBScience
TBS3C	Is variation a glpK a marker for MDR/XDR-TB? – Panel discussion	23 OCT	17:15	18:00	TBScience
TBS4A	Innovations in TB therapeutics – Plenary session	24 OCT	15:00	16:30	TBScience
TBS4B	Innovations in TB therapeutics – Oral abstract presentations	24 OCT	16:30	17:15	TBScience
TBS4C	Innovations in TB therapeutics – Panel discussion	24 OCT	17:15	18:00	TBScience

# Meet the Expert sessions

TITLE	DAY	START	END
Health advocacy for access to care	21 OCT	09:45	10:45
TB vaccine for children	21 OCT	09:45	10:45
The use of technology to deliver care and treatment (communication, patient education, treatment adherence). How we can use technology, to have also remote, support to patients, during special times? And how can we learn from this, also for the general time?	21 OCT	18:15	19:15
BCG protection against COVID-19	22 OCT	09:45	10:45
The external quality assessment of Cepheid GeneXpert® diagnostic assays	22 OCT	18:15	19:15
Health and wellbeing post TB	23 OCT	09:45	10:45
HIV and COVID-19	23 OCT	09:45	10:45
Clinical management of COVID-19	23 OCT	18:15	19:15
Global Epidemics and Pandemics resulting from Zoonotic Diseases: the role of the World Organisation for Animal Health (OIE)	23 OCT	18:15	19:15
Impact of COVID-19 on TB: what is happening in Europe?	24 OCT	09:45	10:45
COVID-19 links to smoking under tobacco industry interference	24 OCT	09:45	10:45